Partnerships Archives

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Nov 2022

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […]

October 26, 2022 - 3 minutesmins - By Liza Laws

More News! 26 Oct 2022

Neuraxpharm to commercialize device giving early warning of epileptic seizures

A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]

October 26, 2022 - 4 minutesmins - By Liza Laws

lupus autoimmune disease neutrophil citryll

News and Trends 26 Oct 2022

Partnership for better understanding of Sjögren’s syndrome announced by Evotec

A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to be generated following a partnership between Evotec SE and a German university. Evotec made the announcement yesterday (Tuesday) that it will work with Hannover Medical School (MHH). The strategic partnership between Evotec and MHH aims at achieving a better understanding […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

Scancell signs agreement with Genmab

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

ABL and RD-Biotech to partner on cell and gene therapy manufacturing

French companies ABL and RD-Biotech have signed a strategic partnership to cover cell and gene therapy (C&GT) GMP manufacturing. ABL, is a contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates. RD-Biotech is a CRO (contract research […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

More News! 24 Oct 2022

Mass production of lutetium for targeted cancer therapeutics following collaboration

An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […]

October 24, 2022 - 4 minutesmins - By Liza Laws

News and Trends 5 Oct 2022

New biotech company aims to bridge gap between stem cell research and athletic injuries

Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of Andrews Celltex Biologics. The new company will undertake the operation of […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

TrialSpark has announced a new partnership with global pharma company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage phase II and phase III drug candidates in areas of high unmet patient need. The partnership […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Partnerships

Alimentiv and Summit collaborate to tackle liver disease NASH

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Drug discovery company signs exclusive license to use university’s technology

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

Neuraxpharm to commercialize device giving early warning of epileptic seizures

Partnership for better understanding of Sjögren’s syndrome announced by Evotec

Scancell signs agreement with Genmab

ABL and RD-Biotech to partner on cell and gene therapy manufacturing

Mass production of lutetium for targeted cancer therapeutics following collaboration

New biotech company aims to bridge gap between stem cell research and athletic injuries

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

Subscribe to our newsletter to get the latest biotech news!